This study will examine the impact of receiving a genetic risk assessment for Alzheimer's disease among individuals with mild cognitive impairment (MCI).
|Min Age||Max Age||Gender||Healthy Volunteers|
Apolipoprotein E (APOE) is a gene that can provide information about a person's chances of developing Alzheimer's disease. Some people with a diagnosis of MCI are curious to learn more about their chance of developing Alzheimer's. We will examine the psychological and behavioral impact of learning genetic information pertaining to the risk of progressing from MCI to Alzheimer's within 3 years.
This study requires participation in an education session, knowledge and attitudinal surveys, and tests to assess memory and thinking skills. Participants with MCI will have their blood drawn for genetic testing and be randomized to one of two groups. Those in the intervention arm will receive a 3-year risk estimate for the chance of progressing to dementia of the Alzheimer's type with the APOE gene test result. Those in the comparison arm will receive a 3-year risk estimate for the chance of progressing to dementia of the Alzheimer's type without the APOE gene test result. The latter group will have the opportunity to learn their own APOE gene test result at the end of the study.
Participants and their study partners will be followed for 6 months following disclosure of results, with one additional clinic visit and one additional phone interview.
|Map Marker||City||State||Zip Code||Status||Primary Contact|
Geolocation is 38.9178427, -77.0218255
District of Columbia
Geolocation is 42.3053253, -83.6694169
Geolocation is 39.9583587, -75.1953934
Brigham and Women's Hospital
National Human Genome Research Institute (NHGRI)
University of Michigan
University of Pennsylvania
Robert C. Green, MD, MPH
Brigham and Women's Hospital/Harvard Medical School
Leo B. Waterston